Literature DB >> 21393330

Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.

Volkhard Seitz1, Philippe E Thomas, Karin Zimmermann, Ulrike Paul, Anke Ehlers, Maria Joosten, Lora Dimitrova, Dido Lenze, Anke Sommerfeld, Elisabeth Oker, Ulf Leser, Harald Stein, Michael Hummel.   

Abstract

BACKGROUND: Epigenetic changes are involved in the extinction of the B-cell gene expression program of classical Hodgkin's lymphoma. However, little is known regarding epigenetic similarities between cells of classical Hodgkin's lymphoma and plasma cell myeloma, both of which share extinction of the gene expression program of mature B cells. DESIGN AND METHODS: Global histone H3 acetylation patterns were determined in cell lines derived from classical Hodgkin's lymphoma, plasma cell myeloma and B-cell lymphoma by chromatin immunoprecipitation and subsequent hybridization onto promoter tiling arrays. H3K27 trimethylation was analyzed by chromatin immunoprecipitation and real-time DNA polymerase chain reaction for selected genes. Epigenetic modifications were compared to gene expression data.
RESULTS: Characteristic B-cell genes were hypoacetylated in classical Hodgkin's lymphoma and plasma cell myeloma cell lines as demonstrated by comparison of their histone H3 acetylation patterns to those of B-cell lines. However, the number of genes jointly hyperacetylated and expressed in classical Hodgkin' lymphoma and plasma cell myeloma cell lines, such as IRF4/MUM1 and RYBP, is limited. Moreover, H3K27 trimethylation for selected characteristic B-cell genes revealed that this additional epigenetic silencing is much more prevalent in classical Hodgkin's lymphoma than in plasma cell myeloma.
CONCLUSIONS: Our epigenetic data support the view that classical Hodgkin's lymphoma is characterized by abortive plasma cell differentiation with a down-regulation of characteristic B-cell genes but without activation of most genes typical of plasma cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21393330      PMCID: PMC3105648          DOI: 10.3324/haematol.2010.031138

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  47 in total

1.  Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression.

Authors:  Alexey Ushmorov; Olga Ritz; Michael Hummel; Frank Leithäuser; Peter Möller; Harald Stein; Thomas Wirth
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

2.  An integrated workflow for analysis of ChIP-chip data.

Authors:  Karin Weigelt; Christoph Moehle; Thomas Stempfl; Bernhard Weber; Thomas Langmann
Journal:  Biotechniques       Date:  2008-08       Impact factor: 1.993

Review 3.  Epigenetic therapy of leukemia: An update.

Authors:  Nitin Jain; Adriana Rossi; Guillermo Garcia-Manero
Journal:  Int J Biochem Cell Biol       Date:  2008-10-17       Impact factor: 5.085

4.  Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line.

Authors:  Einav Nili Gal-Yam; Gerda Egger; Leo Iniguez; Heather Holster; Steingrímur Einarsson; Xinmin Zhang; Joy C Lin; Gangning Liang; Peter A Jones; Amos Tanay
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

5.  Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma.

Authors:  Joost Kluiver; Klaas Kok; Ines Pfeil; Debora de Jong; Tjasso Blokzijl; Geert Harms; Pieter van der Vlies; Arjan Diepstra; Ciğdem Atayar; Sibrand Poppema; Ralf Küppers; Anke van den Berg
Journal:  Hematol Oncol       Date:  2007-03       Impact factor: 5.271

6.  Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers.

Authors:  F M Raaphorst; F J van Kemenade; E Fieret; K M Hamer; D P Satijn; A P Otte; C J Meijer
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

7.  A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4.

Authors:  Serena Valsami; Vassiliki Pappa; Dimitra Rontogianni; Frieda Kontsioti; Efstathios Papageorgiou; John Dervenoulas; Themis Karmiris; Sotirios Papageorgiou; Nikolaos Harhalakis; Nikolaos Xiros; Emmanuel Nikiforakis; Theofanis Economopoulos
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

8.  Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.

Authors:  Daniela Buglio; Georgios V Georgakis; Shino Hanabuchi; Kazuhiko Arima; Noor M Khaskhely; Yong-Jun Liu; Anas Younes
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

9.  Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.

Authors:  Takashi Watanabe; Harumi Kato; Yukio Kobayashi; Satoshi Yamasaki; Yuriko Morita-Hoshi; Hiroki Yokoyama; Yasuo Morishima; Justin L Ricker; Tetsuya Otsuki; Akiko Miyagi-Maesima; Yoshihiro Matsuno; Kensei Tobinai
Journal:  Cancer Sci       Date:  2009-09-10       Impact factor: 6.716

10.  Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.

Authors:  Margarita Sánchez-Beato; Esther Sánchez; Joaquín González-Carreró; Manuel Morente; Ana Díez; Lydia Sánchez-Verde; María Carmen Martín; Juan C Cigudosa; Miguel Vidal; Miguel A Piris
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

View more
  7 in total

1.  PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma.

Authors:  L Dimitrova; V Seitz; J Hecht; D Lenze; P Hansen; M Szczepanowski; L Ma; E Oker; A Sommerfeld; F Jundt; W Klapper; M Hummel
Journal:  Leukemia       Date:  2013-07-11       Impact factor: 11.528

2.  Histone acetylation and DNA demethylation of T cells result in an anaplastic large cell lymphoma-like phenotype.

Authors:  Maria Joosten; Volkhard Seitz; Karin Zimmermann; Anke Sommerfeld; Erika Berg; Dido Lenze; Ulf Leser; Harald Stein; Michael Hummel
Journal:  Haematologica       Date:  2012-08-16       Impact factor: 9.941

Review 3.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

4.  Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation.

Authors:  Clarissa D Osswald; Linka Xie; Hanfeng Guan; Franziska Herrmann; Sarah M Pick; Marion J Vogel; Franziska Gehringer; Fong Chun Chan; Christian Steidl; Thomas Wirth; Alexey Ushmorov
Journal:  Blood       Date:  2018-02-13       Impact factor: 22.113

5.  RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy.

Authors:  Sukesh Voruganti; Fangxiu Xu; Jiang-Jiang Qin; Yan Guo; Sushanta Sarkar; Ming Gao; Zhijie Zheng; Ming-Hai Wang; Jianwei Zhou; Biyun Qian; Ruiwen Zhang; Wei Wang
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

6.  Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.

Authors:  Tao Jiang; Fujue Wang; Lianjie Hu; Xiaomin Cheng; Yuhuan Zheng; Ting Liu; Yongqian Jia
Journal:  Oncotarget       Date:  2017-09-06

Review 7.  Mechanisms of Polycomb group protein function in cancer.

Authors:  Victoria Parreno; Anne-Marie Martinez; Giacomo Cavalli
Journal:  Cell Res       Date:  2022-01-19       Impact factor: 46.297

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.